MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Mink Therapeutics' third quarter 2025 conference call and webcast. All participants will be in a listen-only mode until the question and answer session. Please note this event is being recorded. If anyone has any objections, you may disconnect at this time. I would now like to turn the conference over to Stephanie Perna-Nakar, Chief Communication Officer. Stephanie, please go ahead. Thank you, Operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and commercial plans, timelines for data releases, and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, Dr. Terese Hammond, Head of Development, and Christine Klaskin, Principal Financial and Accounting Officer. I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter. Thank you, Stephanie. Good morning, everyone. This quarter marks a defining period for Mink Therapeutics. We're now a fully independent operating company, focused, agile, and singularly dedicated to advancement of our INKT cell therapy platform. Over the course of this year, we've not only strengthened our science, but also elevated our global visibility, presenting major new findings at ASCO GI, AACRIO, the inaugural meeting, And most recently, last week, at the Society for Immune Therapy of Cancer, the CITSE annual meeting, I think was founded on a bold idea that a single nat...